Volta

Direct-to-consumer self-tests sold in the UK in 2023: cross sectional review of regulation and evidence of performance

Unknown authors · 2025
hash_id: 3185a0f296a7256d68966878a089a0001d8cbf20d45fd6edbc2015033ade180d · DOI: 10.1136/bmj-2025-085547

OBJECTIVES: To review the evidence base, clinical performance claims, and usability and safety of self-tests available for sale on the UK high street. DESIGN: Cross sectional review of self-tests-regulation, evidence of performance, usability, and safety. SETTING: Tests were identified from supermarkets, pharmacies, and health and wellbeing shops within a 10 mile radius of the University of Birmingham Edgbaston Campus in 2023. MAIN OUTCOME MEASURES: Accuracy claims of self-tests, samples used to derive accuracy measures, and regulatory requirements were summarised. Ergonomics, usability and safety concerns about the equipment and instructions, including interpretability and readability, were evaluated. Details of clinical and lay person study reports (population, sample size, reference or comparator tests, test process) were summarised, and methods were assessed using the …

Reference & gravity metrics

Citations
0
Citations / yr
0.00
RCR
Mass
0.00
Depth
0.00
Momentum
0.000
Burn rate
0.00 ATP/day
Start price
25.00 ATP

Secondary-market trade history

No secondary-market trades recorded for this Volta yet.

References (0)

No outbound references recorded.

Cited by (1)

Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection secondary